All In MedTech

FDA Clearance Tracker · P860022-S053

BOSTON EQUALENS/BOSTON EQUALENS II

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Nov 21, 2001 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Nov 21, 2001

Approved

Time to decision

57 days

Received Sep 25, 2001. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P860022-S053
Device name
BOSTON EQUALENS/BOSTON EQUALENS II
Applicant
Bausch & Lomb
Applicant location
Rochester, NY
Received
Sep 25, 2001
Decided
Nov 21, 2001
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P860022

Device type

Device class
Class III
Regulation
21 CFR 886.5916
Specialty
Ophthalmology

Every decision under product code MWL

FDA's approval statement

As written in FDA's record.

APPROVAL FOR WET SHIPPING AND UP TO 30 DAYS STORAGE IN BOSTON ADVANCE COMFORT FORMULA CONDITIONING SOLUTION.

Source documents

Other decisions for Bausch & Lomb

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.